Pancreatic ductal adenocarcinoma is projected to become the second-leading cause of cancer death in the United States by 2030, according to the National Institutes of Health (NIH). The International ...

* 15% of high-risk individuals had main pancreatic duct dilation * Baseline dilation increases progression risk up to 26% in 10 years * Duct dilation + multiple cysts raises the //risk to nearly 50% ...

An intraductal papillary mucinous neoplasm (IPMN) is a benign or noncancerous cyst in the ducts of the pancreas. The cysts are sometimes precancerous, which means they may lead to pancreatic cancer.

As one of the world’s leading experts in pancreatic cancer, Prof Andrew Biankin is all too familiar with the aura of dread ...

Surgeon Siong-Seng Liau was one of those carrying out the surgery on patient Jane Gardner A hospital has carried out the ...

Though not as common as some other types of cancer, pancreatic cancer is one of the most challenging cancers to diagnose and treat. However, advances in medicine over the last decade have led to ...

Please provide your email address to receive an email when new articles are posted on . Patients who underwent early surgery vs. endoscopy-first approach reported a lower Izbicki pain score. Pain was ...

Pancreatic cancer is often called a “silent killer” because it usually does not cause clear or specific symptoms in the early ...

Daraxonrasib, a new pancreatic cancer drug, cut the risk of death by 60% in a Phase 3 trial. A doctor explains how it works, side effects and when it could reach patients.